propranolol has been researched along with Angiogenesis, Pathologic in 28 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity." | 8.12 | Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. ( Bischoff, J; Fontaine, F; Francois, M; Graus, MS; Huang, L; Karnezis, T; McCann, A; Meunier, F; Mulliken, JB; Seebauer, CT; Staffa, SJ; Wylie-Sears, J; Zurakowski, D, 2022) |
| "Propranolol has become the treatment of choice for infantile hemangiomas (IH)." | 7.88 | Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? ( Babiak-Choroszczak, L; Bagłaj, M; Fischer, K; Gawrych, E; Giżewska-Kacprzak, K; Puchalska-Niedbał, L; Rajewska-Majchrzak, J; Walecka, A, 2018) |
| "The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway." | 7.81 | Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015) |
| "Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs." | 7.80 | Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. ( Li, KL; Mai, HM; Qin, ZP; Wang, YA; Zhang, L; Zheng, J; Zheng, JW, 2014) |
| "To determine whether propranolol has an inhibitory effect on the angiogenesis of endometriosis in an experimental rat model or not." | 7.80 | Effects of repeated propranolol administration in a rat model of surgically induced endometriosis. ( Caydere, M; Engin-Ustun, Y; Gulerman, HC; Keskin, SM; Mollamahmutoglu, L; Moraloglu, O; Ozyer, S; Uzunlar, O, 2014) |
| "To investigate the mechanism of propranolol on regression of infantile hemangiomas." | 7.78 | Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. ( Armijo, BS; Chim, H; Gliniak, C; Gosain, AK; Miller, E; Serret, MA, 2012) |
| "Propranolol and atenolol, current therapies for problematic infantile hemangioma (IH), are composed of R(+) and S(-) enantiomers: the R(+) enantiomer is largely devoid of beta blocker activity." | 4.12 | Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma. ( Bischoff, J; Fontaine, F; Francois, M; Graus, MS; Huang, L; Karnezis, T; McCann, A; Meunier, F; Mulliken, JB; Seebauer, CT; Staffa, SJ; Wylie-Sears, J; Zurakowski, D, 2022) |
| " Of these, 14 were proliferating hemangiomas, 14 were stationary, 14 were involuted, and 13 had been treated with propranolol." | 4.02 | NOTCH pathway activation in infantile hemangiomas. ( Johnson, A; Richter, G; Strub, GM; Sun, R; Wei, T; Zhang, H, 2021) |
| "Propranolol has become the treatment of choice for infantile hemangiomas (IH)." | 3.88 | Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas? ( Babiak-Choroszczak, L; Bagłaj, M; Fischer, K; Gawrych, E; Giżewska-Kacprzak, K; Puchalska-Niedbał, L; Rajewska-Majchrzak, J; Walecka, A, 2018) |
| "Propranolol is the first-line drug for treatment of infantile hemangioma." | 3.88 | Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma. ( An, W; Li, S; Sun, C; Wang, W; Xu, W; Yang, X; Yu, F; Zhang, Y, 2018) |
| "Systemic propranolol is currently the first-line treatment modality for complicated infantile haemangiomas." | 3.85 | [Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment]. ( Ábrahám, R; Csoma, ZR; Dalmády, S; Kemény, L; Rácz, K; Rózsa, T, 2017) |
| "The current study demonstrated the antiangiogenic properties of propranolol in vitro and that the drug was able to induce the regression of hemangioma cells via the inhibition of cell cycle progression, invasion, and tube formation, concomitantly with decreased NO and VEGF levels through the down-regulation of the PI3K/Akt/eNOS/VEGF pathway." | 3.81 | Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway. ( Gao, Y; Guo, ZT; Huang, Q; Li, P; Pan, WK, 2015) |
| "Oral propranolol (PRN) has recently been shown to be highly effective for infantile hemangiomas (IHs), and is currently recommended as the first-line treatment of complicated IHs." | 3.80 | Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell. ( Li, KL; Mai, HM; Qin, ZP; Wang, YA; Zhang, L; Zheng, J; Zheng, JW, 2014) |
| "To determine whether propranolol has an inhibitory effect on the angiogenesis of endometriosis in an experimental rat model or not." | 3.80 | Effects of repeated propranolol administration in a rat model of surgically induced endometriosis. ( Caydere, M; Engin-Ustun, Y; Gulerman, HC; Keskin, SM; Mollamahmutoglu, L; Moraloglu, O; Ozyer, S; Uzunlar, O, 2014) |
| "To investigate the mechanism of propranolol on regression of infantile hemangiomas." | 3.78 | Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A. ( Armijo, BS; Chim, H; Gliniak, C; Gosain, AK; Miller, E; Serret, MA, 2012) |
| "Hemangiomas are benign neoplasms of the vasculature frequently encountered in children." | 2.47 | Hemangiomas - current therapeutic strategies. ( Mabeta, P; Pepper, MS, 2011) |
| "When tumors reached 100 mm, mice were treated with CpG-C/vehicle, and 24 hours later the tumor was excised along with P+E/vehicle treatment." | 1.37 | Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses. ( Ben-Eliyahu, S; Benish, M; Goldfarb, Y; Levi, B; Melamed, R; Sorski, L, 2011) |
| " A dosage of 2 mg/kg/d, is usually employed with a dosing interval of 8 hours." | 1.37 | [Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations]. ( López-Gutiérrez, JC; Ruiz-Rodriguez, R; Sánchez-Carpintero, I, 2011) |
| "Portal hypertension was induced by partial portal vein ligation (PVL)." | 1.30 | Increased angiogenesis in portal hypertensive rats: role of nitric oxide. ( Battegay, E; Sieber, CC; Stumm, M; Sumanovski, LT; van der Kooij, M, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.57) | 18.2507 |
| 2000's | 3 (10.71) | 29.6817 |
| 2010's | 21 (75.00) | 24.3611 |
| 2020's | 3 (10.71) | 2.80 |
| Authors | Studies |
|---|---|
| Seebauer, CT | 1 |
| Graus, MS | 1 |
| Huang, L | 1 |
| McCann, A | 1 |
| Wylie-Sears, J | 1 |
| Fontaine, F | 1 |
| Karnezis, T | 1 |
| Zurakowski, D | 1 |
| Staffa, SJ | 1 |
| Meunier, F | 1 |
| Mulliken, JB | 1 |
| Bischoff, J | 1 |
| Francois, M | 1 |
| Zhang, H | 1 |
| Wei, T | 1 |
| Johnson, A | 1 |
| Sun, R | 1 |
| Richter, G | 1 |
| Strub, GM | 1 |
| Moisan, F | 1 |
| Oucherif, S | 1 |
| Kaulanjan-Checkmodine, P | 1 |
| Prey, S | 1 |
| Rousseau, B | 1 |
| Bonneu, M | 1 |
| Claverol, S | 1 |
| Gontier, E | 1 |
| Lacomme, S | 1 |
| Dousset, L | 1 |
| Couffinhal, T | 1 |
| Toutain, J | 1 |
| Loot, M | 1 |
| Cario-André, M | 1 |
| Jullié, ML | 1 |
| Léauté-Labrèze, C | 1 |
| Taieb, A | 1 |
| Rezvani, HR | 1 |
| Csoma, ZR | 1 |
| Dalmády, S | 1 |
| Ábrahám, R | 1 |
| Rózsa, T | 1 |
| Rácz, K | 1 |
| Kemény, L | 1 |
| Zhu, L | 1 |
| Xie, J | 1 |
| Liu, Z | 1 |
| Huang, Z | 1 |
| Huang, M | 1 |
| Yin, H | 1 |
| Qi, W | 1 |
| Yang, Z | 1 |
| Zhou, T | 1 |
| Gao, G | 1 |
| Zhang, J | 1 |
| Yang, X | 2 |
| Babiak-Choroszczak, L | 1 |
| Giżewska-Kacprzak, K | 1 |
| Gawrych, E | 1 |
| Fischer, K | 1 |
| Walecka, A | 1 |
| Puchalska-Niedbał, L | 1 |
| Rajewska-Majchrzak, J | 1 |
| Bagłaj, M | 1 |
| Xu, W | 1 |
| Li, S | 1 |
| Yu, F | 1 |
| Zhang, Y | 1 |
| An, W | 1 |
| Wang, W | 1 |
| Sun, C | 1 |
| Campanelli, R | 1 |
| Codazzi, AC | 1 |
| Poletto, V | 1 |
| Abbà, C | 1 |
| Catarsi, P | 1 |
| Fois, G | 1 |
| Avanzini, MA | 1 |
| Brazzelli, V | 1 |
| Tzialla, C | 1 |
| De Silvestri, A | 1 |
| Tinelli, C | 1 |
| Licari, A | 1 |
| Berra-Romani, R | 1 |
| Zuccolo, E | 1 |
| Moccia, F | 1 |
| Mannarino, S | 1 |
| Rosti, V | 1 |
| Massa, M | 1 |
| Long, Q | 1 |
| Zheng, H | 1 |
| Liu, X | 1 |
| Guo, SW | 1 |
| Zhang, L | 1 |
| Mai, HM | 1 |
| Zheng, J | 1 |
| Zheng, JW | 1 |
| Wang, YA | 1 |
| Qin, ZP | 1 |
| Li, KL | 1 |
| Wrobel, LJ | 1 |
| Le Gal, FA | 1 |
| Uzunlar, O | 1 |
| Ozyer, S | 1 |
| Engin-Ustun, Y | 1 |
| Moraloglu, O | 1 |
| Gulerman, HC | 1 |
| Caydere, M | 1 |
| Keskin, SM | 1 |
| Mollamahmutoglu, L | 1 |
| Pan, WK | 1 |
| Li, P | 1 |
| Guo, ZT | 1 |
| Huang, Q | 1 |
| Gao, Y | 1 |
| Baud, J | 1 |
| Lomri, A | 1 |
| Graber, D | 1 |
| Bikfalvi, A | 1 |
| Zhu, JY | 1 |
| Zhang, W | 1 |
| Ren, JG | 1 |
| Chen, G | 1 |
| Zhao, YF | 1 |
| Wang, D | 1 |
| Wang, Q | 2 |
| Yin, J | 1 |
| Dong, R | 1 |
| Du, X | 1 |
| Lu, J | 1 |
| Wnęk, A | 1 |
| Andrzejewska, E | 1 |
| Kobos, J | 1 |
| Taran, K | 1 |
| Przewratil, P | 1 |
| Lee, JW | 1 |
| Shahzad, MM | 1 |
| Lin, YG | 1 |
| Armaiz-Pena, G | 1 |
| Mangala, LS | 1 |
| Han, HD | 1 |
| Kim, HS | 1 |
| Nam, EJ | 1 |
| Jennings, NB | 1 |
| Halder, J | 1 |
| Nick, AM | 1 |
| Stone, RL | 1 |
| Lu, C | 1 |
| Lutgendorf, SK | 1 |
| Cole, SW | 1 |
| Lokshin, AE | 1 |
| Sood, AK | 1 |
| Annabi, B | 1 |
| Lachambre, MP | 1 |
| Plouffe, K | 1 |
| Moumdjian, R | 1 |
| Béliveau, R | 1 |
| Hajighasemi, F | 1 |
| Hajighasemi, S | 1 |
| Schwartz, RA | 1 |
| Sidor, MI | 1 |
| Musumeci, ML | 1 |
| Lin, RL | 1 |
| Micali, G | 1 |
| Goldfarb, Y | 1 |
| Sorski, L | 1 |
| Benish, M | 1 |
| Levi, B | 1 |
| Melamed, R | 1 |
| Ben-Eliyahu, S | 1 |
| Sánchez-Carpintero, I | 1 |
| Ruiz-Rodriguez, R | 1 |
| López-Gutiérrez, JC | 1 |
| Mabeta, P | 1 |
| Pepper, MS | 1 |
| Albiñana, V | 1 |
| Recio-Poveda, L | 1 |
| Zarrabeitia, R | 1 |
| Bernabéu, C | 1 |
| Botella, LM | 1 |
| Chim, H | 1 |
| Armijo, BS | 1 |
| Miller, E | 1 |
| Gliniak, C | 1 |
| Serret, MA | 1 |
| Gosain, AK | 1 |
| Breier, G | 1 |
| Sumanovski, LT | 1 |
| Battegay, E | 1 |
| Stumm, M | 1 |
| van der Kooij, M | 1 |
| Sieber, CC | 1 |
2 reviews available for propranolol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Infantile haemangiomas: a challenge in paediatric dermatology.
Topics: Adrenergic beta-Antagonists; Cell Proliferation; Hemangioma; Humans; Infant, Newborn; Neovasculariza | 2010 |
Hemangiomas - current therapeutic strategies.
Topics: Angiogenesis Inhibitors; Bleomycin; Child; Cyclophosphamide; Hemangioma; Humans; Interferons; Neovas | 2011 |
26 other studies available for propranolol and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Non-beta blocker enantiomers of propranolol and atenolol inhibit vasculogenesis in infantile hemangioma.
Topics: Animals; Atenolol; Hemangioma; Humans; Mice; Neoplastic Stem Cells; Neovascularization, Pathologic; | 2022 |
NOTCH pathway activation in infantile hemangiomas.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cell Proliferation; Child, Preschool; DNA-Bind | 2021 |
Critical role of Aquaporin-1 and telocytes in infantile hemangioma response to propranolol beta blockade.
Topics: Adrenergic beta-Antagonists; Animals; Aquaporin 1; Cell Line, Tumor; Cell Movement; Hemangioma, Capi | 2021 |
[Infantile haemangioma: clinical and demographic characteristics, experiences in the treatment].
Topics: Adrenergic beta-Antagonists; Child, Preschool; Follow-Up Studies; Hemangioma; Humans; Hungary; Infan | 2017 |
Pigment epithelium-derived factor/vascular endothelial growth factor ratio plays a crucial role in the spontaneous regression of infant hemangioma and in the therapeutic effect of propranolol.
Topics: Apoptosis; Cell Movement; Cell Proliferation; Cells, Cultured; Endothelial Cells; Eye Proteins; Hema | 2018 |
Serum concentrations of VEGF and bFGF in the course of propranolol therapy of infantile hemangioma in children: Are we closer to understand the mechanism of action of propranolol on hemangiomas?
Topics: Child; Fibroblast Growth Factor 2; Hemangioma; Humans; Infant; Neovascularization, Pathologic; Propr | 2018 |
Role of Thrombospondin-1 and Nuclear Factor-κB Signaling Pathways in Antiangiogenesis of Infantile Hemangioma.
Topics: Adrenergic beta-Antagonists; Animals; Cell Proliferation; Endothelial Cells; Female; Hemangioma; Hum | 2018 |
Kinetic and Angiogenic Activity of Circulating Endothelial Colony Forming Cells in Patients with Infantile Haemangioma Receiving Propranolol.
Topics: Adrenergic beta-Antagonists; Antigens, CD34; Calcium; Calcium Signaling; Cell Movement; Chemokine CX | 2019 |
Perioperative Intervention by β-Blockade and NF-κB Suppression Reduces the Recurrence Risk of Endometriosis in Mice Due to Incomplete Excision.
Topics: Adrenergic beta-Antagonists; Animals; Diterpenes; Endometriosis; Epithelial-Mesenchymal Transition; | 2019 |
Propranolol inhibits angiogenesis via down-regulating the expression of vascular endothelial growth factor in hemangioma derived stem cell.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; Blotting, Western; Cell Proliferation; Cells, Cultured; | 2014 |
Inhibition of human melanoma growth by a non-cardioselective β-blocker.
Topics: Adrenergic beta-Antagonists; Adult; Apoptosis; Cell Line, Tumor; Cell Proliferation; Female; Humans; | 2015 |
Effects of repeated propranolol administration in a rat model of surgically induced endometriosis.
Topics: Abdominal Wall; Adrenergic beta-Antagonists; Animals; Disease Models, Animal; Endometriosis; Endomet | 2014 |
Propranolol induces regression of hemangioma cells via the down-regulation of the PI3K/Akt/eNOS/VEGF pathway.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Cell Cycle Checkpoints; Cell Proliferation; Ce | 2015 |
The therapeutic response in Gorham's syndrome to the beta-blocking agent propranolol is correlated to VEGF-A, but not to VEGF-C or FLT1 expression.
Topics: Adolescent; Adrenergic beta-Antagonists; Female; Humans; Lymphangiogenesis; Neovascularization, Path | 2015 |
Characterization of Endothelial Microparticles Induced by Different Therapeutic Drugs for Infantile Hemangioma.
Topics: Cells, Cultured; Dexamethasone; Endothelium, Vascular; Flow Cytometry; Hemangioma; Human Umbilical V | 2015 |
Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis.
Topics: Acute-Phase Proteins; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Bacterial Trans | 2016 |
Molecular and immunohistochemical expression of apoptotic proteins Bax, Bcl-2 and Caspase 3 in infantile hemangioma tissues as an effect of propranolol treatment.
Topics: Angiogenesis Inhibitors; Apoptosis; bcl-2-Associated X Protein; Caspase 3; Cells, Cultured; Female; | 2017 |
Surgical stress promotes tumor growth in ovarian carcinoma.
Topics: Adrenergic beta-Antagonists; Animals; Carcinoma; Cell Line, Tumor; Cell Proliferation; Cytokines; Fe | 2009 |
Propranolol adrenergic blockade inhibits human brain endothelial cells tubulogenesis and matrix metalloproteinase-9 secretion.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Animals; Brain; Brain Neoplasms; Cell Line; En | 2009 |
Effect of propranolol on angiogenic factors in human hematopoietic cell lines in vitro.
Topics: Adrenergic beta-Antagonists; Carcinogens; Enzyme Activation; Humans; Jurkat Cells; Leukemia; Matrix | 2009 |
Improving postoperative immune status and resistance to cancer metastasis: a combined perioperative approach of immunostimulation and prevention of excessive surgical stress responses.
Topics: Analysis of Variance; Animals; Chemotherapy, Adjuvant; Disease Models, Animal; Etodolac; Female; Imm | 2011 |
[Propranolol in the treatment of infantile hemangioma: clinical effectiveness, risks, and recommendations].
Topics: Adrenal Cortex Hormones; Adrenergic beta-Antagonists; Bradycardia; Bronchial Spasm; Clinical Trials | 2011 |
Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.
Topics: Activin Receptors, Type II; Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Animals; Antigens, | 2012 |
Propranolol induces regression of hemangioma cells through HIF-1α-mediated inhibition of VEGF-A.
Topics: Adrenergic beta-Antagonists; Cell Migration Assays; Cell Survival; Dose-Response Relationship, Drug; | 2012 |
Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Animals; Endothelium, Vascular; Humans; Neovas | 2012 |
Increased angiogenesis in portal hypertensive rats: role of nitric oxide.
Topics: Adrenergic beta-Antagonists; Animals; Body Weight; Disease Models, Animal; Hypertension, Portal; Ima | 1999 |